Foxo4 DRI.

Foxo4 DRI is a research compound in the mitochondrial & longevity peptides.

Its biological effect is described in the mechanism section.

It draws interest for mitochondrial & longevity peptides.

F-tier evidence: no meaningful human evidence; support is preclinical or mechanistic.

What it is

FOXO4-DRI is a synthetic senolytic peptide derived from the transcription factor FOXO4 (Forkhead box O4). It is built as a D-retro-inverso (DRI) isoform of FOXO4's p53-interacting region — composed of D-amino acids in reversed sequence — a design that mimics the natural peptide's binding surface while resisting protease degradation. It was first reported by Baar and colleagues in 2017 as a proof-of-concept tool for selectively eliminating senescent ("zombie") cells.

How it works

In senescent cells, FOXO4 protein accumulates and binds the tumor-suppressor p53, sequestering it in the nucleus and preventing p53 from triggering apoptosis — which keeps damaged senescent cells alive. FOXO4-DRI acts as a competitive antagonist that disrupts the FOXO4–p53 interaction, freeing p53 to translocate and activate intrinsic apoptotic signaling (reported downstream involvement of BAX and caspase-3). Because non-senescent cells do not depend on this FOXO4–p53 interaction for survival, the peptide is proposed to kill senescent cells preferentially. A 2025 Nature Communications structural study identified the intrinsically disordered p53 transactivation domain as the binding target of both FOXO4 and FOXO4-DRI, refining the molecular picture.

What the evidence shows

The foundational evidence is preclinical: Baar et al. (Cell, 2017) showed in naturally aged mice that FOXO4-DRI reduced markers of senescence and improved fitness, fur density, and renal function, and counteracted doxorubicin chemotoxicity. Subsequent independent work extended in vitro and animal findings — e.g., selective clearance of senescent cells from in-vitro-expanded human chondrocytes (Huang et al., Frontiers in Bioengineering and Biotechnology, 2021), and rodent studies in vascular endothelium, Leydig cells, and keloid fibroblasts. Critically, there are no completed or registered human clinical trials of FOXO4-DRI; all efficacy data come from cell culture and mouse models. Claims of anti-aging benefit in humans are therefore unproven and rest entirely on preclinical extrapolation.

Safety considerations

Human safety data for FOXO4-DRI do not exist — it has not undergone formal clinical toxicology or trials, so its safety profile in people is unknown. Mechanistically, releasing p53 to drive apoptosis is a double-edged process: off-target or excessive activity could harm healthy proliferating tissues, and the consequences of broad senescent-cell clearance (e.g., effects on wound healing, immune function, or tissue repair) are not characterized in humans. Material sold online is research-use-only and not manufactured to pharmaceutical standards, raising additional concerns about purity, sterility, and contamination. No conclusions about long-term safety can be drawn from the available animal data.

Regulatory status

FOXO4-DRI is an investigational, research-use-only compound. It is not approved by the FDA (or any major regulator) for any indication, is not a marketed drug, and has no DailyMed monograph; it is sold only as a laboratory research chemical.

1. [1]Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Cell, 2017, Vol. 169; Baar MP et al.; PMID 28340339
2. [2]Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes — Frontiers in Bioengineering and Biotechnology, 2021; Huang Y et al.; PMID 33996787
3. [3]The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nature Communications, 2025; Bourgeois B et al.; PMID 40593617
4. [4]FOXO4-DRI: PubMed search of the primary literature — PubMed (NCBI) literature search, all peer-reviewed reports

• Not FDA-approved; highly experimental, mouse-stage research.
• No established human safety or efficacy.

Stack fit

Why not D: held back by human evidence, preclinical depth, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• Foxo4 DRI is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Mitochondrial & longevity peptides class.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The early-evidence lane
3. Why Minimal, and not higher or lower
4. Proven lane vs speculative lane
5. What people report
6. Regulatory status
7. What changed recently